<DOC>
	<DOC>NCT02142608</DOC>
	<brief_summary>Pilot study to evaluate the sensitivity and specificity of BR55 targeting for prostate cancer nodules with Gleason score greater than or equal to 7.</brief_summary>
	<brief_title>A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male, age between 5070 years old Increased PSA level &gt;4 ng/mL Known prostate cancer Scheduled for prostatectomy not earlier than 3 days and not later than 30 days following BR55 administration (with the exception of training cases where this requirement is not applicable) Provides written informed consent and willing to comply with protocol requirements Documented acute prostatitis or urinary tract infections Known to suffer from stable angina pectoris and/or proven coronary disease, or have symptoms suspicious of coronary disease History of any clinically unstable cardiac condition including class III/IV cardiac failure or rightto left shunts Severe cardiac rhythm disorders within the last 7 days Severe pulmonary hypertension or uncontrolled systemic hypertension or respiratory distress syndrome Received a prostate biopsy procedure within 30 days before admission into the study Determined by investigator to be clinically unsuitable for the study Participating in a concurrent clinical trial or has participated in another clinical trial with an investigational compound within the past 30 days</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Ultrasound Imaging</keyword>
</DOC>